In contrast, the combination of N1, FSL-1, R848, and anti-CTLA4 (TheraVacplus) further increased tumor-infiltrating leucocytes, CD4+ T cells and CD8+ T cells, effector/memory T cells, and markedly lowered fractions of tumor-infiltrating cDCs and pDCs. This evidence concerns the gene CTLA4 and neoplasm.